miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype
Metrics: PDF 2530 views | HTML 2581 views | ?
Stefania Tommasi1, Rosamaria Pinto1, Katia Danza1, Brunella Pilato1, Orazio Palumbo2, Lucia Micale 2 and Simona De Summa1
1 IRCCS Istituto Tumori “Giovanni Paolo II”, Molecular Genetics Laboratory, Bari, Italy
2 IRCCS ‘Casa Sollievo della Sofferenza’, Medical Genetics Unit, San Giovanni Rotondo (FG), Italy
Stefania Tommasi, email:
Keywords: breast cancer, BRCAness, microRNA profiling, DNA repair, miR-151-5p
Received: April 21, 2016 Accepted: June 13, 2016 Published: June 30, 2016
In recent years, the assessment of biomarkers useful for “precision medicine” has been a hot topic in research. The involvement of microRNAs in the pathogenesis of breast cancer has been highly investigated with the aim of being able to molecularly stratify this highly heterogeneous disease. Our aim was to identify microRNAs targeting DNA repair machinery, through Affymetrix GeneChip miRNA Arrays, in a cohort of BRCA-related and sporadic breast cancers. Moreover, we analyzed microRNA expression taking into account our previous results on the expression of PARP1, because of its importance in targeted therapy. miR-361-5p and miR-151-5p were found to be overexpressed in PARP1-upregulating BRCA-germline mutated and sporadic breast tumors. Pathway enrichment analysis was performed to identify potential target genes to be analyzed in the validation step in an independent cohort. Our results confirmed the overexpression of miR-151-5p and, interestingly, its role in the targeting of SMARCA5, a chromatin remodeler. This result was also confirmed in vitro, both through luciferase assay and by analyzing endogenous levels of SMARCA5 in MCF-7 cell lines using miR-151-5p mimic and inhibitor. In conclusion, our data showed the possibility of considering the overexpression of PARP1 and miR-151-5p as biomarkers useful to correctly treat sporadic breast cancers, which eventually could be considered as BRCAness tumors, with PARP-inhibitors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.